Campus Lübeck

Sep 2, 2024 | cell.com | Charité Universitätsmedizin Berlin |Campus Lübeck |Cellular Bioengineering |Miltenyi Biotec B.V

KeywordsCD4 T cell exhaustionautoantigen-specific T cellsantigen-reactive T cell enrichment, ARTEautoimmune diseaseneuromyelitis opticaautoimmune hepatitisbullous pemphigoidMOGADCD154Foxp3IntroductionAutoimmune diseases (AIDs) result from the breakdown of self-tolerance mechanisms, leading to a chronic inflammatory autoimmune reaction and to tissue destruction.

Jul 17, 2024 | academic.oup.com | Campus Lübeck

Besides transcatheter edge-to-edge repair (TEER) there are new interventional treatment options for mitral and tricuspid regurgitation in evaluation, such as a complete replacement of the valve through a prosthesis.

Jun 19, 2024 | bmcpsychiatry.biomedcentral.com | Tebartz Van Elst |Campus Lübeck

12 GPs and 14 psychiatrists took part in the study. Five physicians initially interested in the study did not participate, giving no reason. 54% of the participants were female with the average age of the participants being 54 years. On average, participants had 24 years of work experience. Further details of the demographics of our participants are presented in Table 2. The interviews lasted 30 min on average.

May 4, 2024 | academic.oup.com | Campus Lübeck

Atopic dermatitis is a chronic relapsing inflammatory skin disease characterized by intense itch impacting heavily on patients’ and caregivers’ quality of life. Its clinical presentation is accompanied by a variety of type 2 comorbidities, e.g. asthma, hay fever, food allergies. However, current data on cardiovascular comorbidities are inconsistent. To identify risk of cardiovascular diseases in patients with atopic dermatitis.

Sep 26, 2023 | karger.com | Campus Lübeck |Université Paris Descartes |Martin-Luther-University Halle-Wittenberg

Janni: In my opinion, the strength of the NATALEE data is the new treatment option in intermediate risk patients beyond the high-risk situation represented by the MonarchE cohort. In future, I will consider treating these patients according to the trial. In our high-risk patients, we will have two treatment options in future, which are great, given different toxicity profiles. Banys-Paluchowski: This is a very exciting question.